Hosted on MSN

Forget Recursion Pharmaceuticals stock. This is a much better buy.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
GitHub

[gui] java.lang.NullPointerException: Cannot invoke "java.awt.Rectangle.equals(Object)" because "this.bounds" is null

Program args : -Xms128M -XX:MaxRAMPercentage=70.0 -Dawt.useSystemAAFontSettings=lcd -Dswing.aatext=true -Djava.util.Arrays.useLegacyMergeSort=true -Djdk.util.zip ...
IEEE

ReFu: Recursive Fusion for Exemplar-Free 3D Class-Incremental Learning

Abstract: We introduce a novel Recursive Fusion model, dubbed ReFu, designed to integrate point clouds and meshes for exemplar-free 3D Class-Incremental Learning, where the model learns new 3D classes ...
TMCnet

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...
PharmiWeb

Thank you.

Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together ...
BioSpace

Recursion and Roche Ink Multi-Billion Dollar AI Deal

The shares of Utah-based Recursion were climbing this morning after the company announced that it entered into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions ...